– USA, NY – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Nir Naor, CPA, CFA, MBA, LL.M, to its Board of Directors, effective June 20, replacing Malcolm Taub who will retire from the board.
Mr. Naor said, “I am delighted to join BrainStorm at this exciting point in the Company’s evolution. I am impressed by the management team’s vision and in their commitment to serving ALS patients in dire need of new treatments.”
Nir Naor has also joined the Audit Committee as Chairman and the Governance, Nomination, and Compensation Committee as a member.
About Nir Naor
Nir Naor has over 20 years of global work experience as CFO and senior finance leader, with the majority of his career spent at US and European corporations. He has a broad background that includes large pharma and biotech and has overseen organizations with up to $2.5B in sales and $1B in annual spending. His experience includes serving as CFO of Arbor Pharmaceuticals, a PE-backed company and was instrumental in its sale to Azurity Pharma / NovaQuest Capital. He also founded the Portfolio Management function at UCB and later on became UCB’s US CFO. Mr. Naor’s CFO experience includes IPO Preparedness projects, as well as leading turnarounds and finance transformations while overseeing Finance, IT, Investor Relations, Contracting & Pricing, and Commercial Ops functions at AstraZeneca, UCB, and Mölnlycke Healthcare. Before joining the industry, Nir worked as an Investment Banker, specializing in IPOs and M&A, and before that was a commercial Lawyer. In addition, Mr. Naor currently serves as an advisor and advisory board member to several biotech and tech startups.
Mr. Naor is a Certified Public Accountant, Chartered Financial Analyst, and Advocate. He holds a Master of Business Administration from IMD Business School in Switzerland and a master’s degree in Law from Hamburg University in Germany. He also received a bachelor’s degree in Law (LL.B) and BA (Accounting) from Tel Aviv University In Israel.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation from the US Food and Drug Administration (FDA) and the European Medicines Agency for treating amyotrophic lateral sclerosis. BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive MS and was supported by a grant from the National MS Society (NMSS).
Source: https://brainstorm-cell.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
